4D Molecular Valuation
| FDMT Stock | USD 3.93 0.01 0.26% |
At this time, the firm appears to be undervalued. 4D Molecular Therapeutics owns a latest Real Value of $14.27 per share. The recent price of the firm is $3.93. Our model approximates the value of 4D Molecular Therapeutics from evaluating the firm fundamentals such as Return On Asset of -0.26, number of shares shorted of 6.17 M, and Shares Owned By Institutions of 96.09 % as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting 4D Molecular's valuation include:
Price Book 0.3564 | Enterprise Value | Enterprise Value Ebitda (3.55) | Price Sales 4.9 K | Enterprise Value Revenue 8.5715 |
Undervalued
Today
Please note that 4D Molecular's price fluctuation is somewhat reliable at this time. Calculation of the real value of 4D Molecular Therapeutics is based on 3 months time horizon. Increasing 4D Molecular's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
4D Molecular's intrinsic value may or may not be the same as its current market price of 3.93, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.93 | Real 14.27 | Target 45.4 | Hype 3.97 |
The intrinsic value of 4D Molecular's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence 4D Molecular's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of 4D Molecular Therapeutics helps investors to forecast how FDMT stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of 4D Molecular more accurately as focusing exclusively on 4D Molecular's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use 4D Molecular's intrinsic value based on its ongoing forecasts of 4D Molecular's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against 4D Molecular's closest peers.
4D Molecular Cash |
|
FDMT Valuation Trend
4D Molecular's real value is important for investors to make better decisions and a more accurate overall view of 4D Molecular's financial worth over time. Using both 4D Molecular's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
4D Molecular Total Value Analysis
4D Molecular Therapeutics is currently expected to have valuation of (218.3 M) with market capitalization of 181.97 M, debt of 24.61 M, and cash on hands of 241.09 M. The negative valuation of 4D Molecular may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the 4D Molecular fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(218.3 M) | 181.97 M | 24.61 M | 241.09 M |
4D Molecular Investor Information
About 96.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.36. Some equities with similar Price to Book (P/B) outperform the market in the long run. 4D Molecular Therapeutics recorded a loss per share of 2.98. The entity had not issued any dividends in recent years. Based on the analysis of 4D Molecular's profitability, liquidity, and operating efficiency, 4D Molecular Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.4D Molecular Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. 4D Molecular has an asset utilization ratio of 0.006603 percent. This implies that the Company is making $6.6E-5 for each dollar of assets. An increasing asset utilization means that 4D Molecular Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.4D Molecular Ownership Allocation
The majority of 4D Molecular Therapeutics outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to acquire positions in 4D Molecular Therapeutics to benefit from reduced commissions. Hence, outside corporations are subject to a different set of regulations than regular investors in 4D Molecular Therapeutics. Please pay attention to any change in the institutional holdings of 4D Molecular as this could imply that something significant has changed or is about to change at the company.4D Molecular Profitability Analysis
The company reported the previous year's revenue of 37 K. Net Loss for the year was (160.87 M) with loss before overhead, payroll, taxes, and interest of (141.26 M).About 4D Molecular Valuation
The stock valuation mechanism determines 4D Molecular's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of 4D Molecular Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of 4D Molecular. We calculate exposure to 4D Molecular's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of 4D Molecular's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 37 K | 38.9 K | |
| Pretax Profit Margin | -4.3 K | -4.1 K | |
| Operating Profit Margin | -5.1 K | -4.8 K | |
| Net Loss | -4.3 K | -4.1 K | |
| Gross Profit Margin | (4.24) | (4.03) |
4D Molecular Growth Indicators
Investing in growth stocks can be very risky. If the company such as 4D Molecular does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 53.9 M |
4D Molecular Current Valuation Indicators
4D Molecular's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final 4D Molecular's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as 4D Molecular, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use 4D Molecular's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes 4D Molecular's worth.Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.